EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Population pharmacokinetic model and dosing optimization of vancomycin in hematologic malignancies with neutropenia and augmented renal clearance

Tassadit Belabbas, Takaaki Yamada, Nobuaki Egashira, Takeshi Hirota, Kimitaka Suetsugu, Yasuo Mori, Koji Kato, Koichi Akashi, Ichiro Ieiri

Journal of Infection and Chemotherapy · 2023

DOI: 10.1016/j.jiac.2023.01.010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Infection and Chemotherapy, 2023. Verfasst von Tassadit Belabbas und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, …. Hauptthemen laut MEDLINE: Neutropenia, Hematologic Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: Data on the pharmacokinetics (PK) and area under the curve (AUC)-based dosing strategy of vancomycin (VCM) in hematologic malignancies are limited. According to our preliminary narrative review, only a few population PK analyses in hematologic malignancies have been performed. Therefore, we aimed to develop a population PK model, investigate the factors influencing VCM PK, and propose an optimal dosing regimen for hematologic malignancies. METHODS: A retrospective study was conducted in patients with underlying hematologic malignancies treated with VCM. A total of 148 patients were enrolled for population PK modeling. Simulation analyses were performed to identify dosing regimens achieving a target exposure of AUC0-24 of 400-600 mg h/L at the steady-state. RESULTS: The VCM PK data were best described with a one-compartment model. Significant covariates included creatinine clearance (Ccr), diagnosis of acute myeloid leukemia (AML) and neutropenia on VCM clearance (CL), and body weight (WT) on the volume of distribution (Vd). The typical values of CL and Vd were 3.09 L/h (normalized to Ccr value of 90 mL/min) and 122 L/70 kg, respectively. Concerning the effect on VCM dosing, AML patients required 15% higher doses than non-AML patients, independently of renal function. In contrast, for neutropenic patients, only those with augmented renal clearance (ARC, Ccr value ≥ 130 mL/min) required a 10% dose increase compared to non-neutropenic patients. CONCLUSION: AML patients with neutropenia and ARC represent a critical population with a higher risk of VCM underexposure. Thus, individualized dosing adjustment and therapeutic drug monitoring are strongly recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeutropeniaHematologic NeoplasmsHumansVancomycinAnti-Bacterial AgentsRetrospective Studies

Stichwörter der Autor:innen

Augmented renal clearanceDosing regimenHematologic malignanciesNeutropeniaPopulation pharmacokinetic modelVancomycin

Substanzen

VancomycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
  • Department of Pharmacy, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
  • Department of Clinical Pharmacology and Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan; Department of Pharmacy, Kyushu University Ho…
  • Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Belabbas, T., Yamada, T., Egashira, N., Hirota, T., Suetsugu, K., Mori, Y., Kato, K., Akashi, K., & Ieiri, I. (2023). Population pharmacokinetic model and dosing optimization of vancomycin in hematologic malignancies with neutropenia and augmented renal clearance. Journal of Infection and Chemotherapy. https://doi.org/10.1016/j.jiac.2023.01.010

Vancouver

Belabbas T, Yamada T, Egashira N, Hirota T, Suetsugu K, Mori Y, et al. Population pharmacokinetic model and dosing optimization of vancomycin in hematologic malignancies with neutropenia and augmented renal clearance. Journal of Infection and Chemotherapy. 2023. doi:10.1016/j.jiac.2023.01.010

BibTeX
@article{Belabbas2023,
  author = {Belabbas, Tassadit and Yamada, Takaaki and Egashira, Nobuaki and Hirota, Takeshi and Suetsugu, Kimitaka and Mori, Yasuo and Kato, Koji and Akashi, Koichi and Ieiri, Ichiro},
  title = {Population pharmacokinetic model and dosing optimization of vancomycin in hematologic malignancies with neutropenia and augmented renal clearance},
  journal = {Journal of Infection and Chemotherapy},
  year = {2023},
  doi = {10.1016/j.jiac.2023.01.010}
}
Kostenlos starten →